| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL |
2020-001175-32: Clinical study to evaluate the effect of opicapone 50 mg in the pain associated to Parkinson’s disease. |
|
|
| Ongoing | 4 | 176 | Europe | Ongentys, [BIA 9-1067], Capsule, hard, Ongentys | Bial - Portela & Ca, S.A., BIAL-Portela & Ca, S.A., Bial - Portela & Ca, S.A. | Parkinson's disease patients with wearing-off motor fluctuations andassociated pain., Parkinson's disease result in loss of special nerve cells in the brain. This affects movement, cause tremor and stiffness., Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-002754-24: Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations. Estudio clínico en pacientes con EP temprana para investigar el efecto de Opicapone 50 mg o Levodopa 100 mg en el tratamiento de las fluctuaciones motoras. |
|
|
| Ongoing | 4 | 100 | Europe | Capsule, hard, Tablet, Ongentys 50 mg hard capsules, Madopar 125 mg T, tablets, SINEMET 100 mg + 25 mg tablets | Bial - Portela & Ca, S.A., Bial - Portela & Ca, S.A. | Parkinson's Disease (PD) Enfermedad de Parkinson (EP), Parkinson's Disease (PD) Enfermedad de Parkinson (EP), Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT04821687: A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD |
|
|
| Completed | 4 | 169 | RoW | Ongentys 50mg, Madopar Tab. 125 or Perkin Tab. 25-100mg | SK Chemicals Co., Ltd. | Parkinson Disease | 08/22 | 08/22 | | |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
2020-001176-15: Clinical study to investigate if Opicapone 50mg can reduce sleep disorders associated to Parkinson's disease. |
|
|
| Not yet recruiting | 4 | 30 | Europe | Ongentys 50 mg hard capsules, Capsule, Ongentys | Bial - Portela & Ca, S.A., Bial - Portela & Ca, S.A. | Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders., Parkinson's disease patients with associated movement and sleep disorders., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Active, not recruiting | 4 | 22 | Europe | Opicapone, BIA 9-1067 | Bial - Portela C S.A. | Parkinson Disease | 06/23 | 06/23 | | |
| Active, not recruiting | 4 | 106 | Europe | Opicapone, BIA 9-1067, L-DOPA/DDCI, Levodopa | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 06/23 | 06/23 | | |
2020-005011-52: Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopathic Parkinson’s Disease Patients: The EPSILON Study |
|
|
| Not yet recruiting | 3 | 324 | RoW, Europe | Opicapone, BIA 9-1067, Capsule, hard, Ongentys | BIAL – Portela & Cª, S.A., BIAL-Portela & Ca, S.A., BIAL – Portela & Cª, S.A., | Early Idiopathic Parkinson’s disease, Parkinson’s disease in its early stage, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Active, not recruiting | 3 | 410 | Europe | Opicapone 50 mg, Placebo | Bial - Portela C S.A. | Parkinson | 01/24 | 01/24 | | |
ChiCTR2300069899: A multicenter, randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of Opicapone in primary Parkinson's disease patients with fluctuating end-of-life motor symptoms after treatment with levodopa/dopamine decarboxylase inhibitors |
|
|
| Not yet recruiting | 3 | 250 | | placebo ;Opicapone 25mg ;Opicapone 50 mg | Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Fosun Pharmaceutical (Group) Co., Ltd, Sponsor | Idiopathic Parkinson's disease | | | | |
OPAILEC, NCT06432309: Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease |
|
|
| Completed | N/A | 22 | Europe | Opicapone 50 mg, OPC, Duodopa, Levodopa/carbidopa intestinal gel (LCIG) | University Hospital of Ferrara | Parkinson Disease, Effect of Drug | 12/23 | 04/24 | | |
